Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. The PDE3A inhibitor anagrelide (ANA) profoundly suppresses the proliferation of high PDE3A-ex
Acute myeloid leukemia (AML) is a malignant hematopoietic disease with poor prognosis for most patients. Conventional chemotherapy has been the standard treatment approach for AML in the past 40 years
The combination index (CI) values were calculated using the Chou and Talalay mathematical model for drug interaction on Calcusyn software. A CI was equal to 1 denotes additivity; antagonism if the CI>
To identify a novel clinically-relevant therapy, fluvastatin and matrix bound nanovesicles (MBV) were focused in this study. We found that fluvastatin and MBV synergistically enhance optic nerve regen
